Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

OptimizeRx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

OptimizeRx wird ein Gewinn- und Umsatzwachstum von 19.1% bzw. 20.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 28.3% pro Jahr wachsen soll.

Wichtige Informationen

25.4%

Wachstumsrate der Gewinne

28.3%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	27.4%
Wachstumsrate der Einnahmen	20.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24

Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

May 10

Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Mar 29

Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

Feb 21

What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?

Jan 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OPRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	114	-12	N/A	N/A	6
12/31/2024	102	-14	N/A	N/A	6
3/31/2024	78	-18	-6	-5	N/A
12/31/2023	72	-18	-8	-7	N/A
9/30/2023	63	-14	0	2	N/A
6/30/2023	62	-14	2	4	N/A
3/31/2023	62	-14	6	6	N/A
12/31/2022	62	-11	10	11	N/A
9/30/2022	63	-10	6	7	N/A
6/30/2022	64	-7	3	3	N/A
3/31/2022	64	-3	3	3	N/A
12/31/2021	61	0	0	1	N/A
9/30/2021	57	1	-1	-1	N/A
6/30/2021	52	1	-1	-1	N/A
3/31/2021	47	-1	-1	-1	N/A
12/31/2020	43	-2	-6	-6	N/A
9/30/2020	34	-6	-6	-5	N/A
6/30/2020	29	-7	-7	-6	N/A
3/31/2020	27	-5	-8	-6	N/A
12/31/2019	25	-3	-3	-2	N/A
9/30/2019	24	-1	0	1	N/A
6/30/2019	24	1	2	3	N/A
3/31/2019	22	0	2	2	N/A
12/31/2018	21	0	1	1	N/A
9/30/2018	19	0	0	0	N/A
6/30/2018	16	-1	-2	-2	N/A
3/31/2018	14	-1	-2	-2	N/A
12/31/2017	12	-2	N/A	-1	N/A
9/30/2017	10	-2	N/A	-2	N/A
6/30/2017	9	-2	N/A	-1	N/A
3/31/2017	8	-2	N/A	0	N/A
12/31/2016	8	-2	N/A	0	N/A
9/30/2016	7	-2	N/A	0	N/A
6/30/2016	8	-1	N/A	0	N/A
3/31/2016	7	-1	N/A	0	N/A
12/31/2015	7	-1	N/A	1	N/A
9/30/2015	7	0	N/A	1	N/A
6/30/2015	7	0	N/A	0	N/A
3/31/2015	7	0	N/A	0	N/A
12/31/2014	7	-1	N/A	0	N/A
9/30/2014	6	-1	N/A	1	N/A
6/30/2014	6	-1	N/A	1	N/A
3/31/2014	5	-1	N/A	1	N/A
12/31/2013	5	0	N/A	1	N/A
9/30/2013	4	0	N/A	0	N/A
6/30/2013	3	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OPRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OPRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OPRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OPRXDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: OPRXDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OPRX in 3 Jahren voraussichtlich hoch sein wird

OptimizeRx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

OptimizeRx Corporation Reiterates Financial Guidance for the Full Year 2024

Price target increased by 7.5% to US$16.40

OptimizeRx Corporation Revises Earnings Guidance for the Year 2023

Consensus revenue estimates increase by 11%, EPS downgraded

OptimizeRx Corporation Increases Earnings Guidance for the Year 2023

OptimizeRx Corporation Provides Earnings Guidance for the Year 2024

Recent updates

OptimizeRx Corporation, Annual General Meeting, Jun 05, 2024

OptimizeRx Corporation to Report Q1, 2024 Results on May 14, 2024

OptimizeRx Corporation Reiterates Financial Guidance for the Full Year 2024

OptimizeRx Corporation announced delayed annual 10-K filing

OptimizeRx Corporation Announces Changes to its Board

Insider recently sold US$61k worth of stock

Insider notifies of intention to sell stock

Price target increased by 7.5% to US$16.40

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

OptimizeRx Corporation Revises Earnings Guidance for the Year 2023

Consensus revenue estimates increase by 11%, EPS downgraded

New minor risk - Shareholder dilution

OptimizeRx Corporation Increases Earnings Guidance for the Year 2023

OptimizeRx Corporation Provides Earnings Guidance for the Year 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptimizeRx Corporation to Report Q3, 2023 Results on Nov 06, 2023

Optimizerx Corporation to Change the Designation of Stephen L. Silvestro from Chief Commercial Officer to President

OptimizeRx Corporation (NasdaqCM:OPRX) signed an agreement to acquire Healthy Offers, Inc. for $95 million.

OptimizeRx Corp. Unveils a Significant Enhancement to its Omni-Channel Healthcare Engagement Platform

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 13%

New minor risk - Share price stability

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

OptimizeRx Corporation to Report Q2, 2023 Results on Aug 14, 2023

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

Now 22% undervalued after recent price drop

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

OptimizeRx Corporation Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$27.33

Third quarter 2022 earnings: EPS exceeds analyst expectations

OptimizeRx Corporation Reiterates Earnings Guidance for the Year 2022

OptimizeRx Corporation to Report Q3, 2022 Results on Nov 08, 2022

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Chief Commercial Officer recently bought US$50k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

OptimizeRx Corporation Provides Financial Guidance for the Year 2022

OptimizeRx extends reach with Cooler Screens Partnership

OptimizeRx Corporation to Report Q2, 2022 Results on Aug 09, 2022

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

OptimizeRx Corporation Completes Platform Integration of TelaRep One-Click Prescriber Connectivity Solution

OptimizeRx Corporation (NasdaqCM:OPRX) announces an Equity Buyback for $20 million worth of its shares.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OptimizeRx Corporation Reaffirms Financial Guidance for the Year 2022

Consensus forecasts updated

Price target decreased to US$89.75

OptimizeRx Corporation, Annual General Meeting, Jun 09, 2022

OptimizeRx Corporation to Report Q1, 2022 Results on May 04, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Consensus forecasts updated

OptimizeRx Corporation Announces Earnings Guidance for the Full Year 2022

OptimizeRx Corporation to Report Q4, 2021 Results on Feb 24, 2022

Insider notifies of intention to sell stock

Consensus forecasts updated

CEO & Director notifies of intention to sell stock

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Third quarter 2021 earnings released: EPS US$0.002 (vs US$0.019 loss in 3Q 2020)

President & Chief Strategy Officer exercised options and sold US$1.3m worth of stock

Chief Commercial Officer exercised options and sold US$1.0m worth of stock

Price target increased to US$80.50

OptimizeRx Announces Significant Platform Enhancement to Digitize Pharmaceutical Access Solutions

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All